Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: A multicentre, randomized controlled trial

Virology Journal

Volumn 6, Issue , 2009, Pages

  Zheng, Yongli ^a,d   Zhao, Liansan ^a   Wu, Taixiang ^a   Guo, Shuhua ^b   Chen, Yagang ^c   Zhou, Taoyou ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d First Hospital of Yibin   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON DERIVATIVE; ALPHA INTERFERON IB; CONSENSUS INTERFERON; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA; ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON ALFACON-1; RECOMBINANT INTERFERON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT RESPONSE; ADOLESCENT; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68349150347     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-99     Document Type: Article

References (29)

1. Pharmacotherapy of hepatitis B infection: a brief review. DJ Quan, Nephrol Nurs J 2008 35 5 507 10 18856082
2. Hepatitis B. World Health Organisation, Fact sheet 204 2008 http://www.who.int/mediacentre/factsheets/fs204/en/ Accessed 18 November 2008
3. Treatment of hepatitis B virus infection: present and future. R Planas RM Morillas, Gastroenterol Hepatol. 2008 31 6 349 355 10.1157/13123603 18570812
4. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 Update. EB Keeffe DT Dieterich SH Han IM Jacobson P Martin ER Schiff H Tobias, Clin Gastroenterol Hepatol 2008 6 12 1315 41 10.1016/j.cgh.2008.08.021 18845489
5. A review of interferons: fifty years later (19572007). D Ramos-Bello F Ramos-Niembro, Gac Med Mex 2008 144 1 55 65 18619059
6. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. BX Truong Y Seo M Kato K Hamano T Ninomiya M Katayama H Kato Y Yano Y Hayashi M Kasuga, Int J Mol Med 2005 16 2 279 84 16012762
7. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. SM Lin DI Tai RN Chien IS Sheen CM Chu YF Liaw, J Viral Hepat 2004 11 4 349 57 10.1111/j.1365-2893.2004.00512.x 15230858 (Pubitemid 38961880)
8. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. HY Hsu HY Tsai TC Wu CL Chiang YH Ni PJ Chen MH Chang, Liver Int 2008 28 9 1288 97 18397229
9. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepato-cellular carcinoma. JJ Sung KK Tsoi VW Wong KC Li HL Chan, Aliment Pharmacol Ther 2008 28 9 1067 77 10.1111/j.1365-2036.2008.03816.x 18657133
10. Treatment of chronic hepatitis. T Asselah O Lada N Boyer M Martinot P Marcellin, Brit J Gastroenterol Clin Biol 2008 32 89 749 68
11. New paradigms for the treatment of chronic hepatitis. J Fung CL Lai MF Yuen, J Gastroenterol Hepatol. 2008 23 8 Pt 1 1182 1192 10.1111/j.1440-1746. 2008.05400.x 18637060
12. Current antiviral therapies for chronic hepatitis B. M Inada O Yokosuka, Hepatol Res 2008 38 6 535 42 10.1111/j.1872-034X.2008.00323.x 18452480 (Pubitemid 351622278)
13. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. EB Melian GL Plosker, Drugs 2001 61 11 1661 91 10.2165/00003495-200161110-00009 11577799
14. Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. TE Hutson L Molto T Mekhail P Elson J Finke C Tannenbaum E Borden R Dreicer T Olencki RM Bukowski, Clin Cancer Res 2003 9 4 1354 60 12684404
15. Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. L Miglioresi M Bacosi F Russo F Patrizi P Saccenti A Ursitti AD Angelis GL Ricci, Hepatol Res 2003 27 4 253 9 10.1016/S1386-6346(03)00269-9 14662112 (Pubitemid 38009009)
16. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. G Fattovich I Zagni E Minola M Felder P Rovere A Carlotto S Suppressa A Miracolo C Paternoster C Rizzo A Rossini P Benedetti M Capanni C Ferrara P Costa T Bertin M Pantalena L Lomonaco C Scattolini G Mazzella M Giusti S Boccia S Milani R Marin M Lisa Ribero A Tagger, J Hepatol 2003 39 5 843 9 10.1016/S0168-8278(03)00391-X 14568269 (Pubitemid 37372196)
17. Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy. M Steffen M Cornberg P Buggisch, Hepatogastroenterology 2007 54 80 2368 72 18265667
18. Managing chronic hepatitis C in the difficult-to-treat patient. N Kemmer GW Neff, Liver Int 2007 27 10 1297 310 18036096
19. Treatment recommendations of chronic hepatitis B. Did the world escape us? R Flisiak J Jaroszewicz, Przegl Epidemiol 2008 62 1 133 8 18536235
20. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. L Wood M Egger LL Gluud KF Schulz P Jüni DG Altman C Gluud RM Martin AJ Wood JA Sterne, Br Med J 2008 336 7644 601 5 10.1136/bmj.39465.451748.AD
21. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. JM Pawlotsky OG Dusheik A Hatzakis D Lau G Lau TJ Liang S Locarnini P Martin DD Richman F Zoulim, Gastroenterology 2008 134 2 405 15 18242209 10.1053/j.gastro.2007.11.036 (Pubitemid 351181309)
22. Treatment of chronic viral hepatitis. C Pedersen CR Pedersen, Ugeskr Laeger 2008 170 24 2137 40 18565297
23. Advance in technical method and treatment for viral hepatitis. H Kumada, Rinsho Byori 2008 56 2 108 13 18404825
24. Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines. I Colle M Adler R Brenard J Henrion P Langlet P Michielsen H Orlent H Reynaert D Sprengers P Stärkel P Van Damme C Verslype J Delwaide Belgian Association for the Study of the Liver, Acta Gastroenterol Belg 2007 70 4 389 420 18330099
25. Viral hepatitis B: established and emerging therapies. C Balsano A Alisi, Curr Med Chem 2008 15 9 930 9 10.2174/092986708783955383 18473801 (Pubitemid 351736414)
26. Hepatitis B: reflections on the current approach to antiviral therapy. F Zoulim R Perrillo, J Hepatol 2008 48 Suppl 1 S2 19 10.1016/j.jhep.2008.01.011 18304680
27. Managing chronic hepatitis C in relapsers and non-responders. M Montalbano N Kemmer GW Neff, Minerva Gastroenterol Dietol 2008 54 1 31 47 18299666
28. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. M Cornberg J Hadem E Herrmann F Schuppert HH Schmidt M Reiser O Marschal M Steffen MP Manns H Wedemeyer, Turk J Gastroenterol 2006 17 1 35 9 16830275
29. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. WO Böcher M Schuchmann R Link H Hillenbrand F Rahman M Sprinzl J Mudter HF Löhr PR Galle, Liver Int 2006 26 3 319 25 10.1111/j.1478-3231.2005.01239.x 16584394 (Pubitemid 43349322)